Research advances of obinutuzumab in the treatment of membranous nephropathy

• 主要な著者: Xiao-jing Lin (著者), Jing Sun (著者), Hao-yi Xiangli (著者), Xuan-yi Du (著者)
• フォーマット: 図書
• 出版事項: Editorial Department of Journal of Clinical Nephrology, 2024-01-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Membranous nephropathy （MN） is a common cause of adult nephrotic syndrome. Rituximab, a type Ⅰ anti-CD20 monoclonal antibody, is an effective treatment of MN. However, its response rate is merely 60% during a follow-up period of up to 24 months. Obinutuzumab is a type Ⅱ humanized anti-CD20 monoclona...